Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Selective inhibition of histamine-evoked Ca2+ signals by compartmentalized cAMP in human bronchial airway smooth muscle cells.

Dale P, Head V, Dowling MR, Taylor CW.

Cell Calcium. 2018 May;71:53-64. doi: 10.1016/j.ceca.2017.12.002. Epub 2017 Dec 15.

2.

Neurologic complications after allogeneic hematopoietic stem cell transplantation: risk factors and impact.

Dowling MR, Li S, Dey BR, McAfee SL, Hock HR, Spitzer TR, Chen YB, Ballen KK.

Bone Marrow Transplant. 2018 Feb;53(2):199-206. doi: 10.1038/bmt.2017.239. Epub 2017 Nov 13.

PMID:
29131150
3.

Endogenous lysophosphatidic acid (LPA1 ) receptor agonists demonstrate ligand bias between calcium and ERK signalling pathways in human lung fibroblasts.

Sattikar A, Dowling MR, Rosethorne EM.

Br J Pharmacol. 2017 Feb;174(3):227-237. doi: 10.1111/bph.13671. Epub 2017 Jan 6.

4.

Regulation of platelet lifespan in the presence and absence of thrombopoietin signaling.

Lebois M, Dowling MR, Gangatirkar P, Hodgkin PD, Kile BT, Alexander WS, Josefsson EC.

J Thromb Haemost. 2016 Sep;14(9):1882-7. doi: 10.1111/jth.13397. Epub 2016 Aug 11.

PMID:
27344013
5.

Stochastic Measurement Models for Quantifying Lymphocyte Responses Using Flow Cytometry.

Kan A, Pavlyshyn D, Markham JF, Dowling MR, Heinzel S, Zhou JH, Marchingo JM, Hodgkin PD.

PLoS One. 2016 Jan 7;11(1):e0146227. doi: 10.1371/journal.pone.0146227. eCollection 2016.

6.

T cell signaling. Antigen affinity, costimulation, and cytokine inputs sum linearly to amplify T cell expansion.

Marchingo JM, Kan A, Sutherland RM, Duffy KR, Wellard CJ, Belz GT, Lew AM, Dowling MR, Heinzel S, Hodgkin PD.

Science. 2014 Nov 28;346(6213):1123-7. doi: 10.1126/science.1260044.

7.

Why the immune system takes its chances with randomness.

Hodgkin PD, Dowling MR, Duffy KR.

Nat Rev Immunol. 2014 Oct;14(10):711. doi: 10.1038/nri3734-c1. Epub 2014 Sep 12. No abstract available.

PMID:
25212742
8.

Stretched cell cycle model for proliferating lymphocytes.

Dowling MR, Kan A, Heinzel S, Zhou JH, Marchingo JM, Wellard CJ, Markham JF, Hodgkin PD.

Proc Natl Acad Sci U S A. 2014 Apr 29;111(17):6377-82. doi: 10.1073/pnas.1322420111. Epub 2014 Apr 14.

9.

The pharmacological rationale for combining muscarinic receptor antagonists and β-adrenoceptor agonists in the treatment of airway and bladder disease.

Dale PR, Cernecka H, Schmidt M, Dowling MR, Charlton SJ, Pieper MP, Michel MC.

Curr Opin Pharmacol. 2014 Jun;16:31-42. doi: 10.1016/j.coph.2014.03.003. Epub 2014 Mar 27. Review.

10.

Investigating the molecular mechanisms through which FTY720-P causes persistent S1P1 receptor internalization.

Sykes DA, Riddy DM, Stamp C, Bradley ME, McGuiness N, Sattikar A, Guerini D, Rodrigues I, Glaenzel A, Dowling MR, Mullershausen F, Charlton SJ.

Br J Pharmacol. 2014 Nov;171(21):4797-807. doi: 10.1111/bph.12620.

11.

Labour-efficient in vitro lymphocyte population tracking and fate prediction using automation and manual review.

Chakravorty R, Rawlinson D, Zhang A, Markham J, Dowling MR, Wellard C, Zhou JH, Hodgkin PD.

PLoS One. 2014 Jan 3;9(1):e83251. doi: 10.1371/journal.pone.0083251. eCollection 2014.

12.

Quantal and graded stimulation of B lymphocytes as alternative strategies for regulating adaptive immune responses.

Hawkins ED, Turner ML, Wellard CJ, Zhou JH, Dowling MR, Hodgkin PD.

Nat Commun. 2013;4:2406. doi: 10.1038/ncomms3406.

13.

A model for studying the hemostatic consumption or destruction of platelets.

Dowling MR, Josefsson EC, Henley KJ, Kile BT, Hodgkin PD.

PLoS One. 2013;8(3):e57783. doi: 10.1371/journal.pone.0057783. Epub 2013 Mar 7.

14.

The Influence of receptor kinetics on the onset and duration of action and the therapeutic index of NVA237 and tiotropium.

Sykes DA, Dowling MR, Leighton-Davies J, Kent TC, Fawcett L, Renard E, Trifilieff A, Charlton SJ.

J Pharmacol Exp Ther. 2012 Nov;343(2):520-8. doi: 10.1124/jpet.112.194456. Epub 2012 Aug 1.

15.

Reassessment of the pharmacology of Sphingosine-1-phosphate S1P3 receptor ligands using the DiscoveRx PathHunter™ and Ca2+ release functional assays.

Riddy DM, Stamp C, Sykes DA, Charlton SJ, Dowling MR.

Br J Pharmacol. 2012 Oct;167(4):868-80. doi: 10.1111/j.1476-5381.2012.02032.x.

16.

Activation-induced B cell fates are selected by intracellular stochastic competition.

Duffy KR, Wellard CJ, Markham JF, Zhou JH, Holmberg R, Hawkins ED, Hasbold J, Dowling MR, Hodgkin PD.

Science. 2012 Jan 20;335(6066):338-41. doi: 10.1126/science.1213230. Epub 2012 Jan 5.

17.

Platelet life span and apoptosis.

Josefsson EC, White MJ, Dowling MR, Kile BT.

Methods Mol Biol. 2012;788:59-71. doi: 10.1007/978-1-61779-307-3_5.

PMID:
22130700
18.

The in vitro metabolism of sphingosine-1-phosphate: identification; inhibition and pharmacological implications.

Bradley ME, McGuinness N, Williams G, Charlton SJ, Dowling MR.

Eur J Pharmacol. 2011 Dec 15;672(1-3):56-61. doi: 10.1016/j.ejphar.2011.09.178. Epub 2011 Sep 29.

PMID:
21970805
19.

Megakaryocytes possess a functional intrinsic apoptosis pathway that must be restrained to survive and produce platelets.

Josefsson EC, James C, Henley KJ, Debrincat MA, Rogers KL, Dowling MR, White MJ, Kruse EA, Lane RM, Ellis S, Nurden P, Mason KD, O'Reilly LA, Roberts AW, Metcalf D, Huang DC, Kile BT.

J Exp Med. 2011 Sep 26;208(10):2017-31. doi: 10.1084/jem.20110750. Epub 2011 Sep 12.

20.

Automated and semi-automated cell tracking: addressing portability challenges.

Kan A, Chakravorty R, Bailey J, Leckie C, Markham J, Dowling MR.

J Microsc. 2011 Nov;244(2):194-213. doi: 10.1111/j.1365-2818.2011.03529.x. Epub 2011 Sep 6.

21.

[³⁵S]GTPγS binding as an index of total G-protein and Gα-subtype-specific activation by GPCRs.

Mistry R, Dowling MR, Challiss RA.

Methods Mol Biol. 2011;746:263-75. doi: 10.1007/978-1-61779-126-0_14.

PMID:
21607862
22.

Measuring receptor target coverage: a radioligand competition binding protocol for assessing the association and dissociation rates of unlabeled compounds.

Sykes DA, Dowling MR, Charlton SJ.

Curr Protoc Pharmacol. 2010 Sep;Chapter 9:Unit 9.14. doi: 10.1002/0471141755.ph0914s50.

PMID:
22294377
23.

Platelet senescence is regulated by an internal timer, not damage inflicted by hits.

Dowling MR, Josefsson EC, Henley KJ, Hodgkin PD, Kile BT.

Blood. 2010 Sep 9;116(10):1776-8. doi: 10.1182/blood-2009-12-259663. Epub 2010 Jun 7.

24.

Why does the thymus involute? A selection-based hypothesis.

Dowling MR, Hodgkin PD.

Trends Immunol. 2009 Jul;30(7):295-300. doi: 10.1016/j.it.2009.04.006. Epub 2009 Jun 18.

PMID:
19540805
25.

Exploring the mechanism of agonist efficacy: a relationship between efficacy and agonist dissociation rate at the muscarinic M3 receptor.

Sykes DA, Dowling MR, Charlton SJ.

Mol Pharmacol. 2009 Sep;76(3):543-51. doi: 10.1124/mol.108.054452. Epub 2009 Jun 4.

26.

Modelling naive T-cell homeostasis: consequences of heritable cellular lifespan during ageing.

Dowling MR, Hodgkin PD.

Immunol Cell Biol. 2009 Aug-Sep;87(6):445-56. doi: 10.1038/icb.2009.11. Epub 2009 Mar 17.

PMID:
19290017
27.

A model of immune regulation as a consequence of randomized lymphocyte division and death times.

Hawkins ED, Turner ML, Dowling MR, van Gend C, Hodgkin PD.

Proc Natl Acad Sci U S A. 2007 Mar 20;104(12):5032-7. Epub 2007 Mar 14.

28.

Modelling cell lifespan and proliferation: is likelihood to die or to divide independent of age?

Dowling MR, Milutinović D, Hodgkin PD.

J R Soc Interface. 2005 Dec 22;2(5):517-26.

29.

Quantifying the association and dissociation rates of unlabelled antagonists at the muscarinic M3 receptor.

Dowling MR, Charlton SJ.

Br J Pharmacol. 2006 Aug;148(7):927-37. Epub 2006 Jul 10.

30.

Quantum computation as geometry.

Nielsen MA, Dowling MR, Gu M, Doherty AC.

Science. 2006 Feb 24;311(5764):1133-5.

31.

A single point mutation (N514Y) in the human M3 muscarinic acetylcholine receptor reveals differences in the properties of antagonists: evidence for differential inverse agonism.

Dowling MR, Willets JM, Budd DC, Charlton SJ, Nahorski SR, Challiss RA.

J Pharmacol Exp Ther. 2006 Jun;317(3):1134-42. Epub 2006 Feb 17.

32.

In vitro and in vivo pharmacological characterization of 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one (indacaterol), a novel inhaled beta(2) adrenoceptor agonist with a 24-h duration of action.

Battram C, Charlton SJ, Cuenoud B, Dowling MR, Fairhurst RA, Farr D, Fozard JR, Leighton-Davies JR, Lewis CA, McEvoy L, Turner RJ, Trifilieff A.

J Pharmacol Exp Ther. 2006 May;317(2):762-70. Epub 2006 Jan 24.

33.

Time-reversal test for stochastic quantum dynamics.

Dowling MR, Drummond PD, Davis MJ, Deuar P.

Phys Rev Lett. 2005 Apr 8;94(13):130401. Epub 2005 Apr 6.

PMID:
15903973

Supplemental Content

Loading ...
Support Center